Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Phase 2 Recruiting 120 enrolled University of Cologne

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.

Timeline

Start: 2024-05-24
Primary completion: 2026-05
Completion: 2028-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tislelizumab	Monoclonal antibody	300 mg	—

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications